Matthew Ronsheim insider trades: Entasis Therapeutics Holdings (ETTX) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Matthew reports to the SEC
Open-market buys and sales
1 trade reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Oct 19, 2021 | ETTX | ↓ Sell | 3,759 | $3.19 | $12K | Direct | Oct 20, 2021 (1d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
About Matthew Ronsheim's insider trades
Matthew Ronsheim is Chief of Pharma Sciences & MFG at Entasis Therapeutics Holdings (ETTX). Since Oct 19, 2021, Matthew has reported no open-market purchases and 1 sale worth $12K on SEC Form 4. There have been no open-market trades in the last 12 months.
Their filings also include grants and awards (6 filings), shares withheld for taxes (4 filings), shares returned to the company (2 filings), other transactions (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every ETTX insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.